Riluzole is a medicine used to treat a specific type of nerve disease called Amyotrophic Lateral Sclerosis (ALS). It helps slow down the worsening of symptoms in some patients with ALS. It's taken by mouth.
Every report comes from a Lived member, sent anonymously.
Have you tried Riluzole for ALS?
Riluzole is a prescription medicine for amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig's disease, in which the nerve cells that control muscles (motor neurons) gradually stop working. ALS is its only FDA-approved use. Riluzole does not reverse weakness or restore lost abilities. Its purpose is to slow the disease modestly and help people live longer. It has been approved in the US since 1995 and remains a standard part of ALS care: European neurology guidelines recommend offering it to everyone with ALS at diagnosis and continuing it long term. In the US it is available as a generic tablet and as Tiglutik, a thickened liquid that can be easier for people who have trouble swallowing or who use a feeding tube. Rilutek, the original brand-name tablet, and Exservan, a film that dissolved on the tongue, are no longer marketed in the US.
Nerve cells pass signals to one another using chemical messengers, and glutamate is one of the main ones that excites motor neurons. Riluzole is believed to reduce damage to motor neurons by lowering glutamate levels, which may help these cells keep working for longer. That explanation is a working theory rather than a settled fact; the FDA label states that exactly how riluzole helps in ALS is unknown. What the trials do show is the result. People taking riluzole lived longer without needing a tracheostomy (a breathing tube placed through the neck), but their muscle strength and day-to-day function did not measurably improve compared with placebo.
The usual dose is 50 mg twice a day, about 12 hours apart, typically morning and evening. It is taken on an empty stomach, at least 1 hour before or 2 hours after a meal, because food, especially a high-fat meal, reduces how much of the drug the body absorbs. In the main trials, half this daily dose was not clearly better than placebo, and double the dose added no benefit. The Tiglutik liquid contains 50 mg in 10 mL. The bottle should be shaken gently for at least 30 seconds before each dose, and the liquid can be swallowed or given through a PEG tube (a feeding tube placed through the abdominal wall into the stomach). An opened bottle is used within 15 days. If a dose is missed, take it when remembered unless the next dose is nearly due, and do not take two doses together. Liver blood tests are needed before starting and during treatment.
The most common side effects in clinical trials were weakness or low energy, nausea, dizziness, abdominal pain and a dip on lung function tests. Others include vomiting, dry mouth, trouble sleeping, drowsiness, a faster heartbeat, swelling in the ankles or feet, and numbness or tingling around the mouth. If side effects are bothersome, the prescriber may lower the dose and reassess before considering stopping. Liver effects are the main reason for monitoring. Mild rises in liver enzymes on blood tests are common, usually cause no symptoms and tend to appear in the first 3 months. Rarely, riluzole has caused severe liver injury, including deaths. Yellowing of the skin or whites of the eyes, dark urine or pain in the upper right abdomen should be reported to the prescriber right away. Two other uncommon reactions also need a prompt call. Riluzole can cause a severe drop in white blood cells that fight infection, usually in the first 2 months, so any fever or other sign of infection should be reported. It can also cause inflammation of the lung tissue (interstitial lung disease). A new dry cough or breathing that becomes harder should be checked rather than assumed to be ALS itself, and riluzole is stopped if lung inflammation is confirmed. Severe allergic reactions are rare. Swelling of the face or throat, or difficulty breathing or swallowing after a dose, needs emergency care.
The liver clears riluzole mainly through an enzyme called CYP1A2, so anything that slows or speeds that enzyme changes how much drug stays in the body. Medicines that slow it, such as the antibiotic ciprofloxacin, the antidepressant fluvoxamine and birth control pills, can raise riluzole levels and side effects. Smoking speeds its clearance (smokers clear it about 20% faster) and may make it less effective, so tobacco use is worth mentioning to the prescriber. People taking riluzole are also advised to avoid charcoal-broiled foods. Other medicines that can strain the liver, such as allopurinol (a gout medicine), methyldopa (a blood pressure medicine) and sulfasalazine (used for inflammatory bowel disease and arthritis), may add to the risk of liver injury. The prescriber and pharmacist should see a complete list of medicines, including over-the-counter products and supplements. Riluzole levels run higher in people with liver impairment, and it is not recommended for people whose liver enzymes are already more than 5 times the upper limit of normal. Anyone who has had a severe allergic reaction to riluzole should not take it again. There are no studies in pregnant people, but animal studies showed harm to developing offspring at doses similar to those used in humans, so pregnancy plans should be discussed before and during treatment. It is not known whether riluzole passes into breast milk.
Riluzole does not produce a change people can feel. ALS continues to progress while taking it, and strength or function is not expected to improve. The benefit shows up only over time and across groups of people: in the trials, those taking riluzole lived longer without a tracheostomy, and a Cochrane review concluded that it probably extends median survival by about two to three months. Because the benefit is invisible day to day, it helps to weigh that modest gain against the twice-daily schedule, blood tests and side effects. The first months involve the most monitoring, with liver blood tests monthly for the first 3 months and periodically after that. Guidelines recommend continuing riluzole for life once started, lowering the dose or stopping if side effects persist. As swallowing becomes harder, switching from tablets to the liquid, including through a feeding tube, allows treatment to continue. Riluzole is one part of ALS care. Most people are also followed by a multidisciplinary team that may include physical, occupational, speech and respiratory therapists, nutritionists and social workers, and some may be offered other ALS treatments or clinical trials.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Riluzole, what you've noticed, or ask the community a question.